TY - JOUR T1 - Neurological immune-related adverse events of ipilimumab JF - Practical Neurology JO - Pract Neurol SP - 278 LP - 280 DO - 10.1136/practneurol-2012-000447 VL - 13 IS - 4 AU - Ilja Bot AU - Christian U Blank AU - Willem Boogerd AU - Dieta Brandsma Y1 - 2013/08/01 UR - http://pn.bmj.com/content/13/4/278.abstract N2 - Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine. We present three patients with neurological irAEs from ipilimumab treatment: hypophysitis, meningitis and Guillain–Barré syndrome. Once an irAE occurs, ipilimumab should be stopped and corticosteroids started. Usually, ipilimumab-induced irAE symptoms improve within days to weeks, but can be life-threatening if unrecognised. ER -